Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer

被引:7
|
作者
Sakayauchi, Toru [1 ]
Nemoto, Kenji [2 ]
Ishioka, Chikashi [3 ]
Onishi, Hiroshi [4 ]
Yamamoto, Michinori [5 ,6 ]
Kazumoto, Tomoko [7 ]
Makino, Masaoki [8 ]
Yonekura, Ryuji [8 ]
Itami, Jun [9 ]
Sasaki, Shigeru [10 ]
Suzuki, Gen [11 ]
Hayabuchi, Naofumi [11 ]
Tamamura, Hiroyasu [12 ]
Onimaru, Rikiya [13 ]
Yamada, Shogo [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Radiat Oncol, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Yamagata Univ, Fac Med, Dept Radiat Oncol, Yamagata 990, Japan
[3] Tohoku Univ, Sch Med, Dept Clin Oncol, Sendai, Miyagi 980, Japan
[4] Univ Yamanashi, Fac Med, Dept Radiol, Yamanashi, Japan
[5] Kure Med Ctr, Dept Radiat Oncol, Hiroshima, Japan
[6] Chugoku Canc Ctr, Hiroshima, Japan
[7] Saitama Canc Ctr, Dept Radiol, Saitama, Japan
[8] Kagoshima Med Ctr, Dept Radiol, Kagoshima, Japan
[9] Int Med Ctr Japan, Dept Radiat Therapy & Oncol, Tokyo, Japan
[10] Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 390, Japan
[11] Kurume Univ, Sch Med, Dept Radiol, Kurume, Fukuoka 830, Japan
[12] Fukui Prefectural Hosp, Dept Nucl Med, Fukui, Japan
[13] Hokkaido Univ, Grad Sch Med, Dept Radiol, Sapporo, Hokkaido, Japan
来源
JAPANESE JOURNAL OF RADIOLOGY | 2009年 / 27卷 / 03期
关键词
Esophageal cancer; Chemoradiation therapy; Cisplatin; 5-Fluorouracil; SQUAMOUS-CELL CARCINOMA; LOW-DOSE CISPLATIN; RADIATION-THERAPY; DEFINITIVE CHEMORADIOTHERAPY; CONTINUOUS-INFUSION; TRIAL;
D O I
10.1007/s11604-008-0309-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. This study was performed to identify the differences in toxicity and completion rates of various chemotherapy protocols with that goal in mind. A total of 61 patients with esophageal cancer were enrolled in this study between June 2002 and January 2004. The total radiotherapy dose was 64 Gy. Three chemotherapy protocols were used. Arm A comprised daily low-dose cisplatin (CDDP) and 5-fluorouracil (5FU) (CF protocol) (3 mg/m(2) and 180 mg/m(2), respectively). Arm B was intermediate between arm A and C (CDDP 7 mg/m(2) and 5FU 250 mg/m(2) on days 1-5, 8-12, 29-33, and 36-40). Arm C comprised two courses of standard CF (CDDP 70 mg/m(2) on day 1 and 5FU 600 mg/m(2)/24 h on days 1-4). Although there were no significant differences in hematological toxicity between the protocols, leukocytopenia was slightly milder in arm A. Nausea was significantly more severe in arm C. The completion rate was higher in arm A. The 3-year survival rates were 40%, 31%, and 62%, respectively. The daily low-dose CF protocol showed a trend of mild toxicity regarding leukocytopenia. However, we could not find statistical difference between arms. It also showed a better completion rate than the other two arms.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 50 条
  • [21] Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
    Hisanaga Nomura
    Daiki Tsuji
    Shohei Ueno
    Takashi Kojima
    Satoshi Fujii
    Tomonori Yano
    Hiroyuki Daiko
    Ken Demachi
    Kunihiko Itoh
    Toshikatsu Kawasaki
    Investigational New Drugs, 2022, 40 : 420 - 429
  • [22] Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis
    Zhang, Peng
    Xi, Mian
    Li, Qiao-Qiao
    Hu, Yong-Hong
    Guo, Xiaobo
    Zhao, Lei
    Liu, Hui
    Liu, Shi-Liang
    Luo, Li-Ling
    Liu, Qing
    Liu, Meng-Zhong
    ONCOTARGET, 2016, 7 (28) : 44686 - 44694
  • [23] Concurrent chemotherapy with 5-fluorouracil and carboplatin and external radiotherapy for inoperable esophageal carcinoma. A retrospective experience
    Gambaro, G
    Krengli, M
    Masini, L
    Turri, L
    Loi, G
    Prino, A
    Manara, M
    Oro, G
    Manfredda, I
    TUMORI, 2001, 87 (04) : S102 - S102
  • [24] Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study
    Fujita, Y.
    Hiramatsu, M.
    Kawai, M.
    Sumiyoshi, K.
    Nishimura, H.
    Tanigawa, N.
    DISEASES OF THE ESOPHAGUS, 2008, 21 (06): : 496 - 501
  • [25] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Sato, Yasushi
    Takayama, Tetsuji
    Sagawa, Tamotsu
    Okamoto, Tetsuro
    Miyanishi, Koji
    Sato, Tsutomu
    Araki, Hironobu
    Iyama, Satoshi
    Abe, Seiichiro
    Murase, Kazuyuki
    Takimoto, Rishu
    Nagakura, Hisayasu
    Hareyama, Masato
    Kato, Junji
    Niitsu, Yoshiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) : 570 - 576
  • [26] A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer
    Yasushi Sato
    Tetsuji Takayama
    Tamotsu Sagawa
    Tetsuro Okamoto
    Koji Miyanishi
    Tsutomu Sato
    Hironobu Araki
    Satoshi Iyama
    Seiichiro Abe
    Kazuyuki Murase
    Rishu Takimoto
    Hisayasu Nagakura
    Masato Hareyama
    Junji Kato
    Yoshiro Niitsu
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 570 - 576
  • [27] Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis
    Noriyuki Nishiwaki
    Kazuhiro Noma
    Tomoyoshi Kunitomo
    Masashi Hashimoto
    Naoaki Maeda
    Shunsuke Tanabe
    Kazufumi Sakurama
    Yasuhiro Shirakawa
    Toshiyoshi Fujiwara
    Esophagus, 2022, 19 : 626 - 638
  • [28] Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis
    Nishiwaki, Noriyuki
    Noma, Kazuhiro
    Kunitomo, Tomoyoshi
    Hashimoto, Masashi
    Maeda, Naoaki
    Tanabe, Shunsuke
    Sakurama, Kazufumi
    Shirakawa, Yasuhiro
    Fujiwara, Toshiyoshi
    ESOPHAGUS, 2022, 19 (04) : 626 - 638
  • [29] CISPLATIN AND 5-FLUOROURACIL IN THE PRIMARY MANAGEMENT OF SQUAMOUS ESOPHAGEAL CANCER
    KIES, MS
    ROSEN, ST
    TSANG, TK
    SHETTY, R
    SCHNEIDER, PA
    WALLEMARK, CB
    SHIELDS, TW
    CANCER, 1987, 60 (09) : 2156 - 2160
  • [30] Locoregionally advanced nasopharyngeal carcinoma:: Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin -: A phase II study
    Ferrari, D.
    Chiesa, F.
    Codeca, C.
    Calabrese, L.
    Jereczek-Fossa, B. A.
    Alterio, D.
    Fiore, J.
    Luciani, A.
    Floriani, I.
    Orecchia, R.
    Foa, P.
    ONCOLOGY, 2008, 74 (3-4) : 158 - 166